Brookline Capital Markets Predicts NTLA FY2026 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) – Research analysts at Brookline Capital Markets lowered their FY2026 EPS estimates for shares of Intellia Therapeutics in a report released on Thursday, November 5th. Brookline Capital Markets analyst L. Cann now expects that the company will post earnings of ($2.92) per share for the year, down from their prior forecast of ($2.84). The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($3.28) per share. Brookline Capital Markets also issued estimates for Intellia Therapeutics’ FY2029 earnings at $13.90 EPS and FY2030 earnings at $23.26 EPS.

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.11). The firm had revenue of $7.16 million during the quarter, compared to the consensus estimate of $9.74 million. Intellia Therapeutics had a negative return on equity of 64.74% and a negative net margin of 805.75%. The business’s revenue was down 47.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.92) EPS.

Several other research firms have also recently weighed in on NTLA. Wolfe Research cut shares of Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 price target on the stock. in a report on Wednesday, July 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a research report on Thursday, October 15th. Citigroup reiterated a “market outperform” rating on shares of Intellia Therapeutics in a research note on Tuesday, August 25th. Wedbush lifted their target price on shares of Intellia Therapeutics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 9th. Finally, HC Wainwright restated a “buy” rating and issued a $25.00 target price on shares of Intellia Therapeutics in a research note on Wednesday, September 9th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, seven have given a Hold rating and four have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $21.44.

Check Out Our Latest Stock Report on Intellia Therapeutics

Intellia Therapeutics Trading Up 2.1%

Shares of NTLA stock opened at $11.41 on Tuesday. The firm has a 50-day moving average of $12.02 and a 200-day moving average of $13.00. Intellia Therapeutics has a one year low of $7.95 and a one year high of $18.48.

Institutional Investors Weigh In On Intellia Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in shares of Intellia Therapeutics during the 2nd quarter valued at about $260,721,000. Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Intellia Therapeutics by 24.4% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,605,623 shares of the company’s stock valued at $43,484,000 after acquiring an additional 708,094 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Intellia Therapeutics by 20.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,318,110 shares of the company’s stock valued at $29,709,000 after purchasing an additional 386,261 shares during the last quarter. Arrowstreet Capital Limited Partnership bought a new position in shares of Intellia Therapeutics during the first quarter valued at approximately $17,913,000. Finally, Bank of America Corp DE raised its holdings in Intellia Therapeutics by 11.2% in the 1st quarter. Bank of America Corp DE now owns 1,381,703 shares of the company’s stock worth $17,713,000 after purchasing an additional 139,325 shares in the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO John M. Leonard sold 9,000 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $11.99, for a total value of $107,910.00. Following the sale, the chief executive officer owned 1,138,064 shares of the company’s stock, valued at $13,645,387.36. The trade was a 0.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 3.50% of the company’s stock.

Key Intellia Therapeutics News

Investors following NTLA have been watching these news items:

  • Positive Sentiment: HC Wainwright reiterated its “Buy” rating and $25 price target, well above the share price cited in the background, despite trimming its earnings estimates. Intellia Therapeutics analyst coverage
  • Neutral Sentiment: Intellia is scheduled to present at the Jefferies Global Healthcare Conference in London, which may give investors an opportunity to hear company updates, but no new information was reported in the announcement. Conference announcement
  • Negative Sentiment: HC Wainwright lowered its 2026 and 2027 earnings estimates, while Brookline Capital Markets cut its 2026 estimates and reduced projected 2029–2030 EPS. The revisions point to weaker expected earnings, even though the company is still forecast to report losses in the near term. Intellia Therapeutics analyst coverage

Intellia Therapeutics Company Profile

(Get Free Report)

Intellia Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genome-editing treatments for serious diseases. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company uses CRISPR/Cas9 technology to make targeted changes to DNA. Its research includes in vivo therapies, which are designed to edit genes inside a patient’s body, and ex vivo approaches, which involve modifying cells outside the body before they are returned to the patient. Intellia’s investigational programs have included treatments for transthyretin amyloidosis and hereditary angioedema.

Featured Articles

Earnings History and Estimates for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.